Two floors on one screen
The hero states a plan floor. The product rail a scroll below states a higher figure for the tirzepatide lane. The lower of the two names no molecule, so a reader cannot tell what it buys or whether it is the same product.
We have recorded both, because the seller publishes both, and stored the unattached figure against the general GLP-1 category rather than a drug.
A named company and nothing else named
Its privacy policy and its terms both name the operating company, in one consistent form. That is more than several sellers here manage.
Nothing else is named. No compounding pharmacy, no prescribing clinician, no service area, and no statement in either direction about a membership fee.
Mevo Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Tirzepatide (compounded) | $259/mo"Rx Compounded Tirzepatide Injections · GLP-1 / GIP Dual Hormone Therapy · As low as $ 259" in the product rail | September 2026source |
| Glp-1 (compounded) | $199/mo⚠ The hero states "Plans starting as low as $199/month" — a lower floor than any drug on the same page, attached to no named molecule. Both figures are recorded because the seller publishes both | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 240 providers reviewed here are paid partners today; the other 236 are not. See how this works.
See Mevo Health's current price →Good fit if
- Readers who want a per-month tirzepatide figure without an intake.
- Buyers who want the operating company named consistently.
- People comparing a dual-agonist lane against a single-agonist one.
Look elsewhere if
- Anyone who needs the two published floors reconciled.
- Readers who want a named pharmacy or clinician.
- Buyers who need the membership question answered.
- People who need a service-area list.
How this review was verified
- Re-read the homepage, the privacy policy and the terms on 7 September 2026, comparing requested to effective URLs with a nonsense path against the host in the same run, which returned a 404.
- Recorded both published floors rather than choosing between them.
- Stored the unattached figure against the general GLP-1 category, because the hero names no molecule beside it.
- Read the operating company in context on both legal pages and confirmed the two agree.
- Screened the brand and the operating company against FDA’s live warning-letter datatable with both controls green in the same invocation: no letter found.